热门资讯> 正文
Werewolf Therapeutics报告第三季度业绩
2025-11-05 01:21
- Werewolf Therapeutics press release (HOWL): Q3 Net loss of $16.4M vs. $16.7M previous year.
- As of September 30, 2025, cash and cash equivalents were $65.7 million.
More on Werewolf Therapeutics
- Seeking Alpha’s Quant Rating on Werewolf Therapeutics
- Historical earnings data for Werewolf Therapeutics
- Financial information for Werewolf Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
